INVO Bioscience to merge with NAYA Biosciences in all-stock deal; NAYA shareholders to own 88%

INVO Fertility, Inc.

NAYA shareholders receive 7.33333 INVO shares per NAYA share, totaling ~18.15M shares.
Combined company to operate as NAYA Biosciences; Dr. Daniel Teper named Chairman & CEO.
Merger values INVO at $12.4M and NAYA at $90.8M; closing conditions include $5M+ interim PIPE and $5.00/share offering.
Transaction unanimously approved by both boards, expected to close in Q4 2023.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

INVO Fertility, Inc. entered into Agreement and Plan of Merger with NAYA Biosciences, Inc. (effective 2023-10-22).

Action: entry
Agreement: merger
Counterparty: NAYA Biosciences, Inc.
Effective: 2023-10-22

Exact text from the filing

On October 22, 2023, INVO Bioscience, Inc., a Nevada corporation (the “ Company ”), INVO Merger Sub Inc., a wholly owned subsidiary of the Company and a Delaware corporation (“ Merger Sub ”), and NAYA Biosciences, Inc., a Delaware corporation (“ NAYA ”), entered into an Agreement and Plan of Merger, as amended on October 25, 2023 (collectively, the “ Merger Agreement ”).

View on SEC.gov

268 material agreements filed in the last 30 days. Browse all material agreements →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-038408

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.